Qyuns Therapeutics Co., Ltd.
Research Qyuns Therapeutics Co., Ltd. (2509.HK) on Bullrun: market cap HKD 3.57B, P/E 5.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2509.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 3.57B
- P/E5.7
- Financial periodFY2025
- RevenueCNY 806.96M
- Revenue growth408.2%
- Net incomeCNY 314.45M
- Free cash flowCNY 392.23M
- Gross margin88.5%
Valuation Snapshot
latest market cap is HKD 3.57B; P/E is 5.7.
Peer valuation comparison
Latest P/E is 5.67x versus a Healthcare sector median of 21.69x (73.8% below).
Latest P/E is 5.67x versus a China median of 16.26x (65.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 806.96M | CNY 314.45M | CNY 392.23M | 88.5% | n/a | CNY 961.75M | CNY 580.01M | CNY 694.03M |
| FY2024 | CNY 158.79M | -CNY 335.57M | -CNY 187.85M | 58.1% | -1.53 | CNY 360.69M | CNY 527.60M | CNY 228.98M |
| FY2023 | CNY 0 | -CNY 507.75M | -CNY 308.63M | n/a | -2.29 | CNY 216.30M | CNY 346.06M | CNY 294.76M |
| FY2022 | CNY 0 | -CNY 298.19M | -CNY 247.98M | n/a | -1.34 | CNY 213.09M | CNY 295.25M | CNY 641.72M |
| FY2021 | n/a | n/a | n/a | n/a | -1.85 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.57B | 5.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Qyuns Therapeutics Co., Ltd.
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Qyuns Therapeutics Co., Ltd.'s market cap?
Qyuns Therapeutics Co., Ltd.'s market capitalization is HKD 3.57B.
What is Qyuns Therapeutics Co., Ltd.'s P/E ratio?
Qyuns Therapeutics Co., Ltd.'s price-to-earnings (P/E) ratio is 5.7.
What does Qyuns Therapeutics Co., Ltd. do?
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis under the SAILEXIN brand.